Human CTLA-4 Monoclonal Antibody
Product Sizes
1 mg
£355.00
YR0118-1MG
5 mg
£885.00
YR0118-5MG
20 mg
£1721.00
YR0118-20MG
About this Product
- SKU:
- YR0118
- Additional Names:
- ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human CTLA-4
- Isotype:
- IgG1, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0118
